Background and Purpose-The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Our aim was to explore the efficacy of ALB in the ALIAS Part 1 data and to assess the statistical assumptions underlying the ALIAS Part 2 Trial. Methods-ALIAS is a multicenter, blinded, randomized controlled trial. Data on 434 subjects, comprising the ALIAS Part 1 subjects, were analyzed. We examined both the thrombolysis and nonthrombolysis cohorts combined and separately in a "target population" by excluding subjects who would not have been eligible for the ALIAS Part 2 Trial; the latter comprised patients Ͼ83 years of age, those with elevated baseline troponin values, and those with in-hospital stroke. We examined the differences in the primary composite outcome, defined as a modified Rankin Scale score of 0 to 1 and/or a National Institutes of Health Stroke Scale score of 0 to 1 at 90 days after randomization. Results-In the combined thrombolysis plus nonthrombolysis cohorts of the target population, 44.7% of subjects in the ALB group had a favorable outcome compared with 36.0% in the saline group (absolute effect sizeϭ8.7%; 95% CI, Ϫ2.2% to 19.5%). Among thrombolyzed subjects of the target population, 46.7% had a favorable outcome in the ALB group compared with 36.6% in the saline group (absolute effect sizeϭ10.1%; 95% CI, Ϫ2.0% to 20.0%). Conclusions-Preliminary results from the ALIAS Part 1 suggest a trend toward a favorable primary outcome in subjects treated with ALB and support the validity of the statistical assumptions that underlie the ALIAS Part 2 Trial. The ALIAS Part 2 Trial will confirm or refute these results. Clinical Trial Registration-URL: http://www.clinicaltrials.gov/ALIAS. Unique identifier: NCT00235495.
T he Albumin in Acute Stroke (ALIAS) Part 1 Trial randomized patients with acute ischemic stroke within 5 hours from symptom onset to treatment with 25% human albumin (ALB): 2 g/kg infused intravenously over 2 hours or to equivolemic normal saline similarly infused. The trial was initiated with a 2-parallel-cohort design, with 1 cohort receiving standard care thrombolysis and 1 receiving conservative care; randomization to ALB or saline control took place independently in each cohort. Enrollment into the study was suspended prematurely for safety reasons at the recommendation of the National Institutes of Health-appointed Data and Safety Monitoring Board after 434 subjects had been enrolled. Our unblinded analysis of safety data only revealed an excess of early deaths in the ALB treatment group, which was predominantly observed among subjects who were elderly, had clinically severe stroke, received excessive fluid during the first 48 hours of treatment, or had concurrent evidence of myocardial damage (elevated troponin levels at admission). 1 After a halt in enrollment of a year and extensive discussion and protocol revisions, the study was restarted anew as the ALIAS Part 2 Trial with a single-cohort design, but with exclusion of patients who (1) were Ͼ83 years of age;
(2) had troponin T or I levels Ͼ0.1 g/L (ng/mL); or (3) had an in-hospital or periprocedural stroke. Additional major procedural changes in the Part 2 Trial include the mandatory use of a loop diuretic at 18 to 24 hours after treatment, restriction of additional intravenous fluid administration during the first 48 hours after treatment, and comprehensive site retraining to ensure that these changes were implemented. These changes in enrollment criteria and study procedures were made exclusively with knowledge of safety data only; the Steering Committee remained blinded to the efficacy data until ALIAS Part 2 had begun enrollment.
The statistical and methodologic decision to restart the study as an independent study with subsequent planned meta-analysis at the end of Part 2 has provided us an opportunity to examine the Part 1 data for preliminary evidence of treatment efficacy. This also allows us to assess the assumptions made about certain parameters, such as the proportion of good outcomes in the reference (saline) group and the interaction effect between tissue-type plasminogen activator and the study drug. We have recently reported the safety data and considerations for design of the ongoing ALIAS Part 2 Trial. 1 We believed that this was our primary ethical obligation after the trial enrollment was halted. In this report, we examine the ALIAS Part 1 data for preliminary signals of efficacy.
Methods
The ALIAS Part 1 Trial was originally designed as 2 separate but concurrently-implemented double-blind, phase III multicenter trials with 1:1 randomization to 25% ALB (2 g/kg IV administered over 120 minutes) or equivolemic 0.9% saline control. One cohort consisted of subjects who received standard-of-care thrombolytic therapy (intravenous tissue-type plasminogen activator, intra-arterial tissue-type plasminogen activator, endovascular mechanical thrombolysis with approved devices and catheters, or a combination of intravenous and endovascular treatment). The other cohort consisted of subjects who were not thrombolyzed. The administration of thrombolytic therapy was based on local clinical judgment informed by then-current guidelines. 2 The eligibility criteria for the study are shown in the Table in the online-only Data Supplement.
We undertook intense internal debate about whether to plan a single cohort with examination for a thrombolysisϫstudy drug interaction effect or 2 separate parallel cohorts. On the basis of data from the ALIAS Pilot Trial, wherein a potential thrombolysisϫALB interaction was suspected, we elected to proceed with 2 parallel cohorts. 3, 4 The ALIAS Part 1 Trial sought to detect a 10% absolute difference in the primary outcome. This was judged to be the minimal clinically important effect size based on recently completed and ongoing trials in acute stroke. [5] [6] [7] We were particularly interested in the effect of ALB plus thrombolysis, based on the outcome of the ALIAS Pilot Trial. 3 A centralized step-forward, Web-based, 1:1 randomization process was used. 8 All study personnel and subjects were blinded, except for 1 statistician who generated the closed reports for the Data and Safety Monitoring Board and interacted with the Data and Safety Monitoring Board in a partially unblinded manner. A biased-coin minimization algorithm adjusted for clinical site within each cohort. Study drug kits consisted of a 500-mL and a 250-mL bottle of either 25% ALB or saline encased in blinding boxes and delivered via tinted intravenous tubing. ALB was manufactured for the trial by Baxter Healthcare Corp, Westlake Village, CA. A bedside nurse or other personnel not involved with the trial administered the study drug (8 mL/kg) by constant intravenous infusion over 2 hours, Ϯ15 minutes). Subjects weighing 94 kg (207 lbs) or more received a maximum volume of 750 mL.
The primary outcome was assessed at 3 months by a study investigator who was blinded to the subject's treatment. Raters were asked if they knew the treatment assignment at the time of the 3-month assessment, and they were no better than chance at identifying the treatment allocated.
A favorable primary outcome was defined as a National Institutes of Health Stroke Scale score of 0 to 1 and/or a modified Rankin Scale score of 0 to 1 at 90 days after randomization. With a 2-sided type I error probability of 0.05, power of 80% to detect a 10% absolute effect size in the primary outcome, and an assumption of the control group's favorable-outcome proportion to be 40%, the required sample size was 900 in each cohort, or a total of 1800 subjects. Because the primary analysis was based on the intent-to-treat principle, this sample size was inflated to account for crossovers and missing data as well as for 3 interim analyses for overwhelming efficacy or futility.
Owing to premature suspension of the trial after 434 subjects had been enrolled, neither the thrombolytic nor the nonthrombolytic cohort had sufficient power to test the primary hypothesis. The target population for the analysis presented in this article is defined as an intent-to-treat population that would have fulfilled the entry criteria for ALIAS Part 2. Thus, subjects with age Ͼ83 years, elevated troponin (Ͼ0.1 ng/L [g/mL]) or elevated creatine kinase-MB values at baseline, and/or an in-hospital stroke were excluded. Subjects with missing baseline troponin or baseline creatine kinase-MB values (nϭ30) were considered to have a normal value when the 24-hour value was normal. (We did not exclude subjects on the basis of their 48-hour total intravenous fluid volume, as this was not a baseline variable. This variable was a predictor of death in our prior safety analysis of the Part 1 subjects; as a result, the Part 2 protocol has been modified to prevent excess fluid administration.)
Statistical Methods
We used a primary unadjusted analysis and then adjusted for baseline National Institutes of Health Stroke Scale score, as was specified a priori in the statistical analysis plan. Second, we explored the data by using a multivariable approach and assessed primary outcome and death at 90 days. We considered both the 2 cohorts combined as well as the individual thrombolysis and nonthrombolysis cohorts. We performed a sensitivity analysis to assess the effect of 10 missing subject outcomes by imputing a worst-possible-outcome score, as specified in the protocol. We performed a secondary assessment of those subjects who were treated with at least 20% of the expected treatment dose, excluding those who did not receive the study drug; in practice, this excluded all patients who received only 100 mL or less of the study drug. Thus, we examined 5 groupings of subjects: (1) cohort combining thrombolysis and nonthrombolysis groups; (2) thrombolysis cohort only; (3) nonthrombolysis cohort only; (4) thrombolysis cohort treated with at least 100 mL of the study drug; and (5) sensitivity cohort with imputed worst possible outcomes.
Data are presented as standard descriptive statistics. Adjusted estimates of risk ratios (RRs) were derived from a generalized linear model by using a binomial distribution and log link. Multivariable analysis was clustered by site to account for randomization, which was stratified by site.
Results
Among 434 subjects randomized in ALIAS Part 1, 118 (27%) would have been excluded by the new criteria for ALIAS Part 2. These 118 subjects were, by definition, older and had characteristics associated with older age, including a greater proportion of atrial fibrillation and higher baseline serum creatinine values; they were equally randomized into the study drug (52%, nϭ61) and control (48%, nϭ57) groups. The target population for this analysis (nϭ316) was distributed such that 82% were thrombolyzed and 18% were not. The nonthrombolysis cohort was slightly less severely affected neurologically (median National Institutes of Health Stroke Scale score, 10 versus 12; Tables 1 and 2 ). There were no study drug crossovers.
There were 10 subjects (2.3%) with missing 3-month outcomes. The overall absolute effect size in the combined thrombolysis and nonthrombolysis cohorts of the target population was 8.7% (95% CI, Ϫ2.2% to 19.5%). Among subjects who were thrombolyzed, the 90-day risk of a good outcome was 10.1% (95% CI, Ϫ2.0% to 20.0%) greater in the ALB group compared with the saline control group (RRϭ1.3 in unadjusted analysis; Table 3 ). Four subjects in the thrombolysis cohort did not receive the study drug or received Ͻ100 mL. The effect size according to the imputed worst-possible outcomes was 9.9%. As expected, owing to the premature halt in recruitment of the trial, none of the observed effects was statistically significant. Using multivariable analysis, we first considered adjustment for the baseline National Institutes of Health Stroke Scale score because this was prespecified in the statistical analysis plan. More complex models adjusting for age, sex, baseline Alberta Stroke Program Early CT Score, and baseline glucose did not make any substantial difference in the observed estimate of effect size and are not presented. A formal test for an ALBϫthrombolysis interaction did not show any evidence of heterogeneity between the thrombolysis and nonthrombolysis cohorts (Pϭ0.513).
No substantial treatment effect was observed in the nonthrombolysis target population. In the nontarget population (patients who would have been excluded according to the ALIAS Part 2 criteria), the 90-day risk of a good outcome in Peripheral vascular disease 9% (12) 7% (9) Chronic renal failure 6% (7) 8% (11) Past stroke 13% (17) 17% (22) Clinical Baseline NIHSS 11 (9) 12 (9) Baseline ASPECTS 9 (3) the ALB group was statistically inferior compared with that of saline control (RRϭ0.5; 95% CI, 0.2 to 0.8). Thus, post hoc, there was a qualitative difference in the direction of the ALB effect between the nontarget population and the target population.
In the thrombolysis cohort of the target population, the 90-day risk of death in the ALB group was the same as that in the saline control group (RRϭ1.2; 85% CI, 0.6 to 2.3). In the nonthrombolysis cohort of the target population, there was nonsignificant increase in the 90-day risk of death (RRϭ1.7; 95% CI, 0.5 to 5.5). In the combined thrombolysis and nonthrombolysis cohorts of the nontarget population, the rate of 90-day death was 31.6% in the ALB group, which was 15.5% higher than in the saline group (RRϭ1.96; 95% CI, 0.96 to 4.00). Outcomes according to the 90-day modified Rankin Scale score are shown in the Figure. 
Discussion
The clinical need for neuroprotective therapies for acute ischemic stroke has never been greater. These exploratory analyses suggest that ALB therapy potentially offers a 10% absolute benefit and a 25% relative benefit for acute stroke subjects who are concurrently thrombolyzed. No similar benefit was seen in the small nonthrombolysis cohort. It is essential to understand that these are the results of a post hoc and underpowered analysis and will need to be confirmed. Furthermore, the ALIAS Part 2 inclusion and exclusion criteria were derived after review of the safety data only. This is important, because if the inclusion and exclusion criteria used to define the target population for this analysis had been changed on the basis of efficacy, then the result presented here would be a sophism. The excluded patients were equally randomized between saline and ALB arms and not differentially to the study drug arm. Importantly for the current ALIAS Part 2 Trial, this analysis suggests that the current assumptions about effect size and control outcome rates are essentially on target. The control outcome rates are actually slightly lower than the assumed 40%, but this lower number will result in slightly greater power at the current sample size of 1100. Therefore, we can conclude that the Part 2 Trial should be powered adequately to detect a 10% treatment effect and a thrombolysisϫALB treatment interaction.
The putative mechanisms by which ALB might be a promising adjuvant or neuroprotective therapy for stroke are many. 9 -13 The fact that there appears to be more promise in the thrombolytic group may be due to subject selection or perhaps to the role of ALB as a reperfusion-enhancing or reperfusion-sustaining agent. 14 ALB has important antioxidant properties and has been shown to promote perfusion in the microcirculation in preclinical animal models in vivo. 15, 16 These properties suggest that ALB may function in the cerebral microcirculation as a perfusion-enhancing agent rather than merely as a classic neuroprotectant.
The safety message bears repeating. Older subjects or subjects with acute myocardial injury (even if apparently minor, defined as a minimal elevation of troponin levels without ECG changes or clinical cardiac symptoms) or subjects with stroke arising as a complication of hospitalization appear to be at greater risk of death from high-volume ALB. Although we carefully reviewed all deaths in the ALIAS Part 1 Trial, 1 the majority were due to large stroke with or without common complications of stroke, such as pneumonia. However, an excess of cardiopulmonary adverse events was observed. We concluded that the effect of highdose ALB on elderly subjects in ALIAS Part 1 must have been cardiopulmonary, and this interacted with stroke to ALB was 25% human serum albumin. A good outcome (primary outcome of the trial) was defined as having achieved a modified Rankin Scale score of 0 to 1 or an NIHSS score of 0 to 1 at 90 days after randomization.
ALB indicates albumin; NIHSS, National Institutes of Health Stroke Scale. *Adjusted for baseline NIHSS score.
Figure.
Modified Rankin Scale (mRS) outcomes at 90 days in the Albumin in Acute Stroke Part 1 target population, thrombolysis cohort (that is, age Ͻ83 years, normal baseline troponin values, and out-of-hospital stroke) who were treated with at least 100 mL of the study drug.
produce the poor outcomes. 1 Recent data suggest that patients without known congestive hart failure who have elevated baseline serum troponin T levels will have a greater mortality compared with those without elevated troponin levels. Some of our patients may therefore have been susceptible to adverse outcomes. 17 We can speculate that lower doses or longer infusion times might have been tolerated better in this group, but this hypothesis needs to be tested. The safety of ALIAS Part 2 is being very closely monitored with frequent safety review by the Executive Committee, the medical safety monitors (blinded to treatment assignment), and the Data and Safety Monitoring Board (unblinded to treatment assignment). Overall, in the ALIAS Part 1 Trial, the absolute effect size in the thrombolyzed target population was Ϸ10%. The ALIAS Part 2 Trial (NCT00235495) is ongoing and will directly verify whether this result can be replicated in an adequately powered, randomized, clinical trial.
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Inclusions
Acute ischemic stroke Age 18 years or older Baseline NIH Stroke Scale (NIHSS) score of 6 or greater as assessed immediately prior to tPA treatment in the thrombolytic cohort, or immediately prior to randomization in the nonthrombolytic cohort Initiation of ALB/placebo treatment within 5 hours of stroke onset, and within 60 minutes of the start of IV tPA, if given Signed and dated informed consent Exclusions Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6 months Known valvular heart disease with CHF in the last 6 months Severe aortic stenosis or mitral stenosis Cardiac surgery involving thoracotomy in the last 6 months Acute myocardial infarction (MI) in the last 6 months Signs or symptoms of acute MI on admission Suspicion of aortic dissection on admission Acute tachy-or brady-arrhythmia with hemodynamic instability on admission Any findings of CHF on physical examination (jugular venous distention, 3 rd heart sound, resting tachycardia > 100/min attributable to CHF, abnormal hepatojugular reflux, lower extremity pitting edema attributable to CHF or unexplained bilateral rales; and/or definite evidence of pulmonary edema on chest x-ray (if performed -not required) Current acute or chronic lung disease requiring supplemental O 2 therapy Historical modified Rankin Scale ≥ 2 Profound dehydration Fever, defined as core body temperature > 37. 5 o C (99.5 o F) Serum creatinine > 2.0 mg/dL (180 umol/L) Severe anemia (hemoglobin < 7.5 g/dL) Intracranial hemorrhage of any type on baseline CT or MRI scan History of or known allergy to albumin, or to natural rubber latex Pregnancy (women of childbearing age must have negative pregnancy test) Concurrent participation in any other therapeutic clinical trial Evidence of any other major life-threatening or serious medical condition that would impair completion of the trial, impair outcome-assessment, or in which ALB therapy might be contraindicated or harmful
